Houston med-aesthetic company acquired in $550M deal

M&A

Houston-based Soliton, which has created a technology that uses sound to treat cellulite and scars, has been acquired. Photo via soliton.com

A California company has acquired Houston-based Soliton as well as its innovative device that uses sound to eliminate cellulite.

Allergan Aesthetics, an AbbVie company, has announced an agreement to acquire Soliton and its rapid acoustic pulse device RESONICTM, which recently received U.S. Food and Drug Administration clearance for the treatment of cellulite.

The company's team first developed the basis of the tool for tattoo removal and earned FDA clearance for that treatment a few years ago. Christopher Capelli and Walter Klemp co-founded Soliton in 2012.

The acquisition will take Soliton's technology to the next level, says Klemp, who serves as the company's executive chairman.

"Allergan Aesthetics' brand recognition, global footprint, track record and commitment to developing best-in-class aesthetic treatments makes the Company ideally suited to maximize the commercial potential of the RESONICTM rapid acoustic pulse technology," Klemp says in the release.

"I am proud of the passion and accomplishments of the Soliton team and thankful for the ongoing support of our investors which have culminated in this transaction," he continues. "We look forward to working with Allergan Aesthetics to ensure a successful completion of this transaction."

For Carrie Strom, president of Global Allergan Aesthetics and senior vice president at AbbVie, Soliton's solution has a great potential in the market. Soliton's clinical trial data that was submitted to the FDA showed that after a single treatment session, RESONICTM demonstrated significant improvement and strong patient satisfaction with 92.9 percent of subjects agreeing or strongly agreeing their cellulite appeared improved, per the release.

"There is a huge unmet need to address cellulite and effective treatments have been elusive and frustrating for consumers," Strom says in the release. "Soliton's technology offers a new, completely non-invasive approach with clinically-proven results to reduce the appearance of cellulite with no patient downtime.

"The addition of this technology complements Allergan Aesthetics' portfolio of body contouring treatments," she continues. "Health care providers will now have another option to address consumers' aesthetic concerns."

Brad Hauser, CEO of Soliton, previously told InnovationMap that the company's plans for 2021 included focusing on the commercialization of their product and get it into the hands of dermatologists, plastic surgeons, and other medical professionals for 25 key accounts — potentially including ones Houston — with a plan for a national rollout in 2022.

Houston-based Moleculin Biotech now has four different oncology treatment currently in trials. Getty Images

Houston cancer-fighting biotech company introduces its 4th ongoing clinical trial

health report

A Houston-based biotech company has wrapped up enrollment for its most recent clinical trial of its cancer-fighting drug.

Moleculin Biotech Inc. (Nasdaq: MBRX) has launched its fourth ongoing trial — this time focusing on Cutaneous T-Cell Lymphoma, or CTCL, treatment. The company's other three trials include treatment for glioblastoma, an aggressive brain cancer, pancreatic cancer, one of the most virulent killers in oncology, and acute myeloid leukemia, or AML.

To treat these various types of cancers, Moleculin has a several drugs it's in preclinical or clinical trials testing — most biotech companies have only one they focus on. WP1220 is the drug that will be used in this trial for topical CTCL treatment of the cancer's resulting skin lesions.

"We believe there continues to be an unmet need for an improved topical therapy for Stage I-III CTCL skin lesions," says Walter Klemp, Moleculin's chairman and CEO, in a news release, "especially one that may avoid significant unwanted side effects."

WP1220 is what's known as a p-STAT3 inhibitor. STAT3 is a transcription factor that encourages tumor development. Moleculin's technology directly attacks the tumor, but also quiets T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

"This proof of concept, if successful, could be an important first demonstration of a therapeutic effect in humans from such a p-STAT3 inhibitor," Klemp continues. "We are pleased with how quickly this trial reached full recruitment and we are hopeful to be able to announce results from this trial yet this year."

Klemp founded the company in 2007, and Moleculin went public in 2016. Now, with the company's four clinical trials, Moleculin is even closer to saving lives with its products.

"Notwithstanding the relatively rare nature of CTCL, we believe showing activity with one of our STAT3 inhibitors, within our WP1066 family of molecules, could be an indicator of both the value of p-STAT3 as a target and the potential for our drugs in other cancers where STAT3 is highly activated," Klemp says in the release.

From cryotherapy and NASA-inspired fitness to startup funding and biotech, this week's innovators to know are raising the bar on health tech and innovation. Courtesy photos

4 health-focused Houston innovators to know this week

Who's who

This week's innovators to know are focused on health and wellness, from a Houston-based cryotherapy franchise to the person behind funding medical device and digital health startups. We couldn't narrow these folks down to the usual three, so here are the four Houston innovators to know as we start the last week in February.

Juliana Garaizar, director of the Texas Medical Center Venture Fund

Courtesy of TMC

Juliana Garaizar has worked all around the world, and her international contacts and venture capital experience has landed her at the heart of the Texas Medical Center leading the TMC Venture Fund.

"I think TMC wants to be positioned as a strong competitor to the East and West Coasts as a point of entry for companies coming to the United States, but also for technology and commercializations from hospitals," she tells InnovationMap. "The fact that I'm already very connected to other countries — not only from the funding side but also from the research side, is really helpful."

Garaizar has her hands full running the $25 million nonprofit fund that invests around $2 million a year. Recipients, which all have a connection to TMC either through the accelerator or workspaces, receive a range between $250,000 to $500,000, and can go up to $1 million in a deal, Garaizar says. She is focused on securing deal flow for the fund before growing it more.

"In the long term, we would like to raise a bigger fun, around $100 million fund," she says. "We would need to make sure we have our deal flow ready for that, and a big part of that would be international deal flow."

Walter Klemp, chairman and CEO of Moleculin

Courtesy of Moleculin

It's pretty concerning to Walter Klemp that, while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he tells InnovationMap. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The company has three core technologies currently being tested with some success, but the most promising is called WP1066, which uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The active compound both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

Jay Sutaria, founder and lead trainer of Sutaria Training & Fitness

Courtesy of ST&F

Earthbound Houstonians have a chance to use NASA training equipment thanks to Jay Sutaria's company, Sutaria Training & Fitness.

"It's exclusive access to the equipment that is not available openly in Houston," Sutaria tells InnovationMap. "NASA is a reference for us to become better trainers."

Sutaria founded his company in 2011 while he was a student at the University of Houston, and the company now operates with two trainers. His clients include professional athletes such as D.J. Augustin (Orlando Magic, NBA); and Tim Frazier (New Orleans Pelicans, NBA), however, Sutaria and his team offer professional personal training services to any type of athlete.

Kyle Jones, COO of iCRYO

Courtesy of iCryo

Kyle Jones says he's always known he was destined for entrepreneurship, and when he came across the potential of cryotherapy while working at a physical therapist office, he knew it was a scalable business.

He opened his first location of iCRYO in League City in 2015. Now the company is

Jones says he used the location to work out the kinks of his business model, since he didn't really have much to model after. One thing that was most important to Jones, with his PT background, was safety of the patients. He cared about this more than making money, he says.

"I knew first and foremost the one thing that the cryotherapy space didn't have was a certification program, which is kind of terrifying to me," Jones tells InnovationMap. "Any therapy has some type of schooling or certification — massage therapy and acupuncture both have it. Cryotherapy even to date does not a certification to it."

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston space tech company develops new engine features with NASA funding

testing 1, 2, 3

Outfitted with a new type of aerospace technology, a rocket engine developed by Houston startup Venus Aerospace for hypersonic flights will undergo testing this summer.

Supported by a $155,908 federal Small Business Innovation Research (SBIR) grant from NASA, Venus Aerospace came up with a new design for nozzles — engine parts that help manage power — for its compact rocket engine. Venus Aerospace says the newly configured nozzles have “exceeded expectations” and will be incorporated into Venus’ upcoming ground-based engine testing.

“We’ve already proven our engine outperforms traditional systems on both efficiency and size,” Venus Aerospace CEO Sassie Duggleby says. “The technology we developed with NASA’s support will now be part of our integrated engine platform — bringing us one step closer to proving that efficient, compact, and affordable hypersonic flight can be scaled.”

The engine at the heart of Venus’ flight platform is called a rotating detonation rocket engine (RDRE). Venus says it’s the first U.S. company to make a scalable, affordable, flight-ready RDRE.

Unlike conventional rocket engines, Venus’ RDRE operates through supersonic shockwaves, called detonations, that generate more power with less fuel.

“This is just the beginning of what can be achieved with Venus propulsion technology,” says Andrew Duggleby, chief technology officer at Venus, founded in 2020. “We’ve built a compact high-performance system that unlocks speed, range, and agility across aerospace, defense, and many other applications. And we’re confident in its readiness for flight.”

Last fall, the company unveiled a high-speed engine system that enables takeoff, acceleration, and hypersonic cruising — all powered by a single engine. While most high-speed systems require multiple engines to operate at different speeds, Venus’ innovation does away with the cost, weight and complexity of traditional propulsion technology.

Among other applications, the Venus system supports:

Spacecraft landers
Low-earth-orbit satellites
Vehicles that haul space cargo
Hypersonic drones and missiles

Nvidia announces plans to produce AI supercomputers at new Texas plants

Manufacturing News

Nvidia announced Monday that it will produce its artificial intelligence supercomputers in the United States for the first time.

The tech giant said it has commissioned more than 1 million square feet of manufacturing space to build and test its specialized Blackwell chips in Arizona and AI supercomputers in Texas — part of an investment the company said will produce up to half a trillion dollars of AI infrastructure in the next four years.

“The engines of the world’s AI infrastructure are being built in the United States for the first time,” Nvidia founder Jensen Huang said in a statement. “Adding American manufacturing helps us better meet the incredible and growing demand for AI chips and supercomputers, strengthens our supply chain and boosts our resiliency.”

Nvidia’s announcement comes as the Trump administration has said that tariff exemptions on electronics like smartphones and laptops are only a temporary reprieve until officials develop a new tariff approach specific to the semiconductor industry.

White House officials, including President Donald Trump himself, spent Sunday downplaying the significance of exemptions that lessen but won’t eliminate the effect of U.S. tariffs on imports of popular consumer devices and their key components.

“They’re exempt from the reciprocal tariffs but they’re included in the semiconductor tariffs, which are coming in probably a month or two,” U.S. Commerce Secretary Howard Lutnick told ABC’s “This Week” on Sunday.

Nvidia said in a post on its website that it has started Blackwell production at Taiwan Semiconductor Manufacturing Co. chip plants in Phoenix. The Santa Clara, California-based chip company is also building supercomputer manufacturing plants in Texas — with Foxconn in Houston and Wistron in Dallas.

Nvidia's AI super computers will serve as the engines for AI factories, “a new type of data center created for the sole purpose of processing artificial intelligence,” the company said, adding that manufacturing in the U.S. will create “hundreds of thousands of jobs and drive trillions of dollars in economic security over the coming decades."

Mass production at both plants is expected to ramp up in the next 12-15 months, Nvidia said. The company also plans on partnering with Taiwan-based company SPIL and Amkor for “packaging and testing operations” in Arizona.

In a statement Monday, the White House called Nvidia’s move “the Trump Effect in action.”

Trump “has made U.S.-based chips manufacturing a priority as part of his relentless pursuit of an American manufacturing renaissance, and it’s paying off — with trillions of dollars in new investments secured in the tech sector alone,” the White House said.

Earlier this year, Trump announced a joint venture investing up to $500 billion for infrastructure tied to artificial intelligence by a new partnership formed by OpenAI, Oracle and SoftBank. The new entity, Stargate, was tasked with building out data centers and the electricity generation needed for the further development of the fast-evolving AI in Texas, according to the White House.

The initial investment is expected to be $100 billion and could reach five times that sum.

Houston XR training company lands $5.8M contract with Air Force

taking flight

The U.S. Air Force’s AFWERX innovation arm has picked Houston-based HTX Labs to provide AI-enabled immersive training for workers who maintain Boeing KC-135 refueling tankers.

HTX Labs, an extended reality (XR) company and provider of immersive training programs for U.S. armed forces, will receive as much as $5.8 million in military funding for this project.

The new initiative comes on the heels of HTX Labs completing the second phase of a virtual KC-135 maintenance training program in partnership with Mildenhall, a Royal Air Force station in England. HTX Labs received Small Business Innovation Research (SBIR) funding for the second-phase project.

Under the new initiative, part of its EMPACT training platform, HTX Labs will develop a virtual AI-powered classroom for workers who maintain the KC-135’s F108 engine. In conjunction with this project, HTX Labs will collaborate with the Maine Air National Guard’s 101st Air Refueling Wing Maintenance Squadron on improving EMPACT.

Major Ryan Wing of the Maine Air National Guard says KC-135 maintenance workers “have limited opportunities to perform some of the more complex aircraft and engine repairs in a training environment. Providing immersive training to our warfighters is essential to ensuring mission readiness.”

In January, HTX Labs tapped Brian Reece as vice president of strategic accounts for the Air Force. In this role, he oversees HTX Labs’ relationship with this military branch. Reece is a retired Air Force colonel.

In 2022, Dallas-based Cypress Growth Capital invested $3.2 million in HTX Labs, which was founded in 2017.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME